Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP304024.RAV9vHa6tpGRtwKAPGa59YrRHOFf4-3rBMktzjLj4Eys0130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP304024.RAV9vHa6tpGRtwKAPGa59YrRHOFf4-3rBMktzjLj4Eys0130_provenance.
• NP357254.RA7AMRZh_NH9fwEOSZbE1roZn07sJRnF5ylxSnfdX274U130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP357254.RA7AMRZh_NH9fwEOSZbE1roZn07sJRnF5ylxSnfdX274U130_provenance.
• NP910020.RAAMPwDRuZXwhPNhcgvISVIZ_l4qFIi2UJ-WoSYRIqT_g130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910020.RAAMPwDRuZXwhPNhcgvISVIZ_l4qFIi2UJ-WoSYRIqT_g130_provenance.
• NP308461.RA9XkqEZa-BDgYx7kF6UYoSCdLk_ONTWLLzUz_qGvNBfQ130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308461.RA9XkqEZa-BDgYx7kF6UYoSCdLk_ONTWLLzUz_qGvNBfQ130_provenance.
• NP308470.RA4z22a15o6pjdlF6FMAflXyxqQ6inqQiD34UVAZ58dB4130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308470.RA4z22a15o6pjdlF6FMAflXyxqQ6inqQiD34UVAZ58dB4130_provenance.
• assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP910016.RA0uRL16JFUSmUyMWY5eYJaB8HqySgJJcanvLsKrr2kvE130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910016.RA0uRL16JFUSmUyMWY5eYJaB8HqySgJJcanvLsKrr2kvE130_provenance.
• NP910019.RA0vTawd3XdBLtLv-Sw4IePrnvm1-l7YiRI3sdstTQVQk130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910019.RA0vTawd3XdBLtLv-Sw4IePrnvm1-l7YiRI3sdstTQVQk130_provenance.
• NP910022.RA8ZzuNlkmJTXXBJcWHtQrDRw8G0tfZSZEAaXrSO9_VRk130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910022.RA8ZzuNlkmJTXXBJcWHtQrDRw8G0tfZSZEAaXrSO9_VRk130_provenance.
• NP308466.RALP9R79pnHRkK81Dh0H4-R6W6eqOzOe2N3UZv6L-B7R8130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308466.RALP9R79pnHRkK81Dh0H4-R6W6eqOzOe2N3UZv6L-B7R8130_provenance.
• NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308475.RAEe1J9_RRqqG2ea_9xR8jWMKjqjyzZ1ytv0LxpKVphBY130_provenance.
• NP910017.RAbBXLNU97VIVKix_r139Gg13MpG119JA43CR3mqnMycU130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910017.RAbBXLNU97VIVKix_r139Gg13MpG119JA43CR3mqnMycU130_provenance.
• assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP496335.RAH6dOXs9YQ2VOULI_-VBPljip_zebGrUlJWiVR0s24vU130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496335.RAH6dOXs9YQ2VOULI_-VBPljip_zebGrUlJWiVR0s24vU130_provenance.
• NP496360.RAFejTp6-rHdi0-PFYEue6GXZLdCDZwXW_Xfvm2qt8nCM130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496360.RAFejTp6-rHdi0-PFYEue6GXZLdCDZwXW_Xfvm2qt8nCM130_provenance.
• NP496439.RAFPxQ7TUORVobjyI3hWi2yYCyvupkhbNo5lttn1qwyz0130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496439.RAFPxQ7TUORVobjyI3hWi2yYCyvupkhbNo5lttn1qwyz0130_provenance.
• NP496326.RAiej1u5S01Qh2WC6xq7cmo_vf9FkinFzo6K9842f92lA130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496326.RAiej1u5S01Qh2WC6xq7cmo_vf9FkinFzo6K9842f92lA130_provenance.
• NP910024.RAOUzu__OOBinm1VUYD09MsGoSuAhTxJberJsaHffMsUc130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910024.RAOUzu__OOBinm1VUYD09MsGoSuAhTxJberJsaHffMsUc130_provenance.
• NP910025.RAvnhinUHi_HANDTTiISH3oKJKJaW5N1FvJtGCPLwA3kI130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910025.RAvnhinUHi_HANDTTiISH3oKJKJaW5N1FvJtGCPLwA3kI130_provenance.
• NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.